An interventional study of smaller incision, new generation implantable miniature telescope (SING-IMT) in Age-Related Macular Degeneration and Geographic Atrophy, sponsored by VisionCare, Inc.. Withdrawn. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.
Sponsored by VisionCare, Inc. · Not applicable, Interventional, and Treatment
The objective of this single center study is to determine the safety of the smaller incision, new generation (SING), implantable miniature telescope (IMT) in a small sample of patients with moderate-severe central vision loss due to late-stage age-related macular degeneration (AMD) in an Israeli Cohort
The SING IMT has CE Mark in the EU and has been implanted in over 200 patients globally including a pivotal study in the U.S. currently underway (the Concerto Study) and a post-marketing study in EU (The PMCF Study). Model SING is a new injectable model based on the IMT parent model (PMA P050034). Following completion of informed consent, patients will be evaluated for eligibility to enroll into the study, including assessment of their best-corrected distance- and near- visual acuity with refraction, and also when using an external telescope simulator to determine if they are likely to benefit from receiving the SING IMT. If eligible, they will be scheduled for out-patient surgery to implant the IMT during routine cataract surgery in one eye. Following implantation, patients will return for 5 post-operative follow-up visits over a period of approximately 12 months. Additionally, patients will have up to 10 rehabilitation/training visits with a low vision specialist to learn how to use the fellow eye for ambulation and the eye with the implant for magnified viewing during daily activities.
1,474 studies on the registry are indexed under Macular Degeneration; 206 are open to participants now.
Browse Macular Degeneration studies →VisionCare, Inc. is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
For Both Eyes:
For the Implanted Eye:
For the Non-Implanted Eye:
-Have adequate peripheral vision at the Pre-operative Visit to allow navigation.
Exclusion Criteria:
For Both Eyes:
Have any of the following conditions at the Pre-operative Visit:
For the Implanted Eye:
For the Non-Implanted Eye:
-Have ophthalmic pathology at the Pre-operative Visit that compromises the patient's peripheral vision based on the Investigator's judgment.
The SING IMT is implanted in on eye and safety endpoints are aimed at following that eye over time post-implant
Device: smaller incision, new generation implantable miniature telescope (SING-IMT)
The IMT (model SING) is an intraocular implant comprised of 2 micro lenses in a glass tube (optics) in a flexible silicone carrier (haptics)
Safety: Endothelial cell density
Percent change in endothelial cell density (ECD) from Pre-operative Visit in study
Time frame: Comparison of baseline to Visit 5 (330 to 420 days post-operatively)
Adverse Events
Rates of adverse events from Operative Visit through Visit 5
Time frame: Approximately 12-months post-operatively (330-420 days)
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is withdrawn, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
VisionCare, Inc.